Hostname: page-component-6bf8c574d5-xtvcr Total loading time: 0 Render date: 2025-02-25T18:43:22.002Z Has data issue: false hasContentIssue false
  • English
  • Français

Sabril

Published online by Cambridge University Press:  18 September 2015

Rights & Permissions [Opens in a new window]

Abstract

An abstract is not available for this content so a preview has been provided. As you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Other
Information
Canadian Journal of Neurological Sciences , Volume 24 , Issue 4 , November 1997 , pp. A-48
Copyright
Copyright © Canadian Neurological Sciences Federation 1997

References

References:

1.Grant, SM and Heel, RC. Vigabatrin: A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in epilepsy and disorders of motor control. Drugs, 1991;41(6):889–926.CrossRefGoogle ScholarPubMed
2.Arzimanoglou, AA, Dumas, C, Chirardl, L et coll. Multicentre clinical evaluation of vigabatrin (Sabril) in mild to moderate partial epilepsies. Epilepsia. 1995;36(S3).Google Scholar
3.Reynolds, EH, Ring, HA, Farr, IN et coll. Open, double-blind and long-term study of vigabatrin in chronic epilepsy. Epilepsia, 1991;32(4):530–538.CrossRefGoogle ScholarPubMed
4.Dodrill, CB, Arnett, JL, Sommerville, KW and Sussman, NM. Effects of differing dosages of vigabatrin (Sabril) on cognitive abilities and quality of life in epilepsy. Epilepsia, 1995;36(2):164–173.Google ScholarPubMed